Larger COPD programs have focused on clinical outcomes (exacerbations, lung function) rather than MMP-axis biomarkers, and registered roflumilast trials rarely prespecify MMP-9 as an endpoint, making definitive conclusions difficult [104]. This evidence concerns the gene MMP9 and chronic obstructive pulmonary disease.